Professor Amit Nathwani’s journey to create a one-shot cure for haemophilia A

To mark World Haemophilia Day, we sit down with Professor Amit Nathwani of the UCL Cancer Institute to explore his journey to commercialising the groundbreaking haemophilia A treatment, Roctavian. Host Nigel Campbell is joined by Prof Nathwani and Dr. Rick Fagan, UCLB Director of Biopharm, to explore how Amit’s work looking after patients with haemophilia in the NHS instilled a mission to develop a 'one and done' vaccine type approach to the condition. Amit’s lab to market story, working with UCLB, led to the creation of Roctavian, a one-time gene therapy used for the treatment of adults with severe haemophilia A. The therapy, which was licensed to BioMarin Pharmaceutical Inc, received marketing approval in Europe in 2022 and US FDA approval in 2023, and is now available to patients commercially. Date of episode recording: 2024-04-10T00:00:00Z Duration: 00:23:58 Language of episode: English Presenter: Nigel Campbell Guests: Prof Amit Nathwani; Dr Rick Fagan Producer: Nora Amin

Om Podcasten

UCL (University College London) is consistently ranked among the world's top ten universities (QS World University Rankings 2010 - 2021). Our excellence extends across all academic disciplines, from one of the world's foremost centres for research and teaching in the biological sciences to world-renowned centres for architecture (UCL Bartlett), education (UCL IOE) and fine art (UCL Slade School). UCL is London's leading multidisciplinary university, with more than 13,000 staff and 43,000 students from 150 different countries. Founded in 1826 in the heart of London, UCL was the first university in England to welcome students of any religion and the first to welcome women on equal terms with men. UCL Minds brings together UCL’s knowledge, insights, and ideas through events, activities, and digital content open to everyone. Find out what’s on UCL Minds: www.ucl.ac.uk/minds